According to EurekaAlert, Novo Biosciences Inc., a spinoff of the MDI Biological Laboratory in Bar Harbor, Maine, has announced that it has received a two-year, $1.5 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the development of MSI-1436 as a potential regenerative medicine therapy for the treatment of patients who have suffered an acute heart attack. “We believe MSI-1436 has enormous potential,” said Kevin Strange, Ph.D., CEO of Novo Biosciences and president of the MDI Biological Laboratory. “No drug now exists to treat heart attack. Heart disease is the the world’s leading killer. In order to advance MSI-1436 into clinical trials, we need to first test its effectiveness in a large animal model. We are deeply grateful to the National Heart, Lung, and Blood Institute for making this possible.” Read more
Related Posts
Business Leaders: Deborah Bronk steers Bigelow Lab expansion to boost reach, programming
Deborah Bronk is president, CEO and a senior research scientist at Bigelow Laboratory for Ocean Sciences in East Boothbay, which will...
UNE retains R2 Research status, reinforcing leadership in scientific advancement
The University of New England has retained its status as one of the country’s leading research universities with the recent release...
Maine college students investigate health effects of forever chemicals
Two dozen Maine college students are investigating the public health effects of forever chemicals by using zebrafish as human stand-ins and...